Trikafta® Cost Making Cystic Fibrosis Treatment Impossible? Explore How To Get Affordable Generic Triko Globally

Summary - Trikafta® costs nearly $350,000 per year in the US and prices are similar in most countries as only the branded version is widely available. Until now, there was no realistic affordable alternative for patients outside well-funded health systems. This blog explains the story behind the first quality-assured generic Trikafta version, how the Cystic Fibrosis Buyer's Club made it possible, and how MedsPartner helps CF patients worldwide access it through compliant personal importation.

Cystic fibrosis affects approximately 188,000 people worldwide, yet only 27% are on treatment. The gap is almost entirely explained by one thing: price. Trikafta® (elexacaftor/tezacaftor/ivacaftor) transformed CF outcomes when it launched in 2019, but at a US list price of approximately $370,000 per year, it has remained inaccessible to the majority of CF patients globally. Vertex Pharmaceuticals is the only brand offering the drug in most countries, and until recently, no affordable alternative existed anywhere.

That changed in June 2026, when the first patients in the world received a generic ETI therapy - branded Triko - from Beximco Pharmaceuticals in Bangladesh, in a milestone marking years of patient-led advocacy. MedsPartner now facilitates access to this generic for Cystic Fibrosis patients worldwide through compliant personal importation.

How does Trikafta® work? What is its mechanism of action against Cystic Fibrosis?

Trikafta® is a triple-combination medicine approved for patients aged 2 years and older with Cystic Fibrosis who have at least one copy of the F508del mutation, or another responsive mutation. The FDA first approved it in October 2019 for patients aged 12 and older, with approvals subsequently extended to younger age groups.

In Cystic Fibrosis, the CFTR gene mutation causes the CFTR protein - which acts as a channel controlling salt and fluid movement in cells - to either not be produced correctly or not function properly. This leads to the thick mucus that clogs the airways, progressively damages the lungs, and affects other organs, including the pancreas.

Trikafta® addresses this at the protein level through three components working together -

• Elexacaftor and tezacaftor are CFTR correctors that help the misfolded protein reach the cell surface and remain stable there

• Ivacaftor is a CFTR potentiator - once the protein is at the surface, ivacaftor helps it open and function properly as a channel

Any latest updates on Elexacaftor/Tezacaftor/Ivacaftor I should know of?

Vertex's patents on Trikafta® are still active in most countries. So how does a generic version exist at all?

The answer lies in Bangladesh's legal status as a Least Developed Country (LDC) under the WTO. Under TRIPS (Trade-Related Aspects of Intellectual Property Rights) rules, LDC nations are exempt from pharmaceutical patent obligations - meaning manufacturers in Bangladesh can legally produce patented medicines without a licence from the originator. This is the legal foundation that made a generic Trikafta® version possible.

The Cystic Fibrosis Buyer's Club - a patient-led group that grew out of the UK-based Right to Breathe campaign - identified this pathway after years of fighting Vertex's pricing strategy. The CFBC's work stretches back to 2019, when they used an earlier buyers' club model to help UK families access Orkambi (a predecessor Vertex CF drug) via an Argentinian manufacturer. That version was an expensive generic and came with significant challenges. This time, after years of effort, the CFBC partnered directly with Beximco Pharmaceuticals in Bangladesh - a company whose LDC status removes the patent barrier entirely.

The initiative was publicly announced at the North American Cystic Fibrosis Conference in Seattle on October 23, 2025. On June 15, 2026, the first patients collected Triko directly from the manufacturer in Dhaka, in a ceremony attended by patients from the US, UK, Slovakia, Qatar, South Africa, and Bangladesh. MedsPartner further simplifies the process by facilitating doorstep delivery as a more convenient option. Read the latest story in the New York Times featuring MedsPartner and new access pathways for CF patients." 

What are the two dosage options with generic Trikafta® variants?

There are two treatment regimens available through MedsPartner -

• Full dose (standard regimen): The complete ETI regimen as prescribed in the Trikafta® label - two elexacaftor/tezacaftor/ivacaftor tablets in the morning and one ivacaftor tablet in the evening, every day. This is the standard approach for most patients.
  
  
• Dose sparing regimen: A lower-dose, reduced-frequency protocol used alongside a standard antibiotic, developed for patients who are responding well to ETI therapy. This regimen costs considerably less per month. The CFBC has published a guide on dose sparing - it is worth discussing with your CF specialist to understand whether it is appropriate for your situation.

Why is Trikafta® so expensive, and why wasn't a generic available sooner?

Vertex Pharmaceuticals holds an extensive portfolio of patents on Trikafta's active ingredients, formulations, and combinations in most countries. These patents extend well into the 2030s and have been aggressively defended - including through legal challenges in India, South Africa, Brazil, and elsewhere where patient groups have tried to invalidate secondary patents. The result: until the CFBC's LDC workaround, no manufacturer outside patent-free jurisdictions could legally produce ETI therapy.

Trikafta® is also priced as a precision therapy for a rare disease - a relatively small patient population supporting the full cost recovery of an expensive and lengthy development programme. 

Even in countries where Trikafta is reimbursed, patients with inadequate insurance face significant copay exposure. In countries where it isn't reimbursed at all, the full private price is unmanageable for virtually all families.

For patients aged 12+ and children aged 6-11 over 30kg:

For children aged 6-11 under 30kg:

Full monthly pricing details, including pack sizes and processing charges, are available on the MedsPartner product page. The generic is manufactured by Beximco Pharmaceuticals - a US FDA, EMA and TGA certified manufacturer in Bangladesh, meeting international regulatory quality standards.

Is the international personal import of generic versions of Trikafta® legal?

Yes. Many countries permit personal import of essential medicines in limited quantities for individual use, with a valid prescription and compliance with destination-country requirements. MedsPartner, in association with CFBC, facilitates access to generic ETI for patients worldwide through this pathway. We guide the patients and their families regarding all the paperwork and help with all necessary information regarding the import permit application, facilitating doorstep international delivery or in-person pick-up in Bangladesh.

Over 30,000 patients across 45+ countries have used MedsPartner to access medicines they would otherwise be unable to afford or obtain locally. We are delighted to extend this service to families dealing with the high costs of cystic fibrosis treatment.

How can I place an order for generic Trikafta® variant on MedsPartner?

Start by reviewing the product details and pricing on the MedsPartner Triko product page and submitting an order request. Once your prescription is received, the team reviews it, checks the import requirements applicable in your country, and advises on any supporting documentation needed. We then offer complete support with documentation and facilitation of compliant personal importation of the generic Trikafta® variant as per your country’s rules.

Important - current availability of generic Trikafta® alternative and early success stories

The initial supply of Triko is being managed on a first-come first-serve basis. We are receiving 5-6 inquiries for the medicine daily from patients and families around the world. The first 50 patients are being prioritised, with international doorstep deliveries expected by July 2026. A small number of patients have already collected directly from the manufacturer in Bangladesh - this is also an option that MedsPartner can facilitate for those willing to travel. The next batch is expected in November 2026. If you place your order now, you will be added to the waiting list and contacted before November with the next steps.

FAQs on Trikafta® & affordable generic (Triko)

Q1. Is the generic version of Trikafta® from MedsPartner as effective as branded Trikafta®?

A - The active ingredients are identical to those in branded Trikafta® and the generic is produced to bioequivalence standards by a facility meeting FDA, EMA, and TGA certification requirements. Your CF specialist monitors lung function and clinical response in the same way regardless of which version you take.

Q2. How much can I save by switching to generic ETI from MedsPartner?

A - Branded Trikafta® costs approximately $350,000 per year in the US. The generic ETI through MedsPartner costs around $12,750 annually for adults and $6,375 for children on the full dose - savings of approximately 96-98%. For patients on the dose sparing regimen, costs are even lower. Full monthly pricing is on the product page.

Q3. Is it legal to import generic ETI for personal use?

A - In most countries, yes - personal import of prescription medicines in limited quantities is permitted for patients with a valid prescription. MedsPartner's team can explain how this works in your country and process your order in line with your local personal import laws. We guide you regarding all documentation and customs requirements to ensure your order reaches you seamlessly.

Q4. How can I trust the quality of generic Trikafta® version from MedsPartner?

A - The generic ETI (Triko) is manufactured by an FDA/EMA-approved facility that also holds TGA (Australia) certification - one of the most comprehensive sets of international regulatory approvals a pharmaceutical manufacturer can carry. Manufacturer details and expiry information are provided with every order. Patient reviews of MedsPartner’s services are available on Trustpilot, where we hold a 4.8-star rating. MedsPartner operates in association with the Cystic Fibrosis Buyer's Club (CFBC), the patient-led organisation that drove the development of this generic and supports patients through the access process.

Q5. I am a doctor. How can I get a generic ETI (Trikafta® alternative) for my patients?

A - Email support@medspartner.com with your patient's prescription and details. The MedsPartner team will reach out to your patient directly, verify all documents, and coordinate access through the personal import pathway in line with the patient's local import regulations.

Q6. What are the common side effects of Trikafta®?

A - Common side effects include headache, upper respiratory tract infections, abdominal pain, diarrhea, rash, and elevated liver enzymes. Liver function is monitored through blood tests, particularly in the first year of treatment. Regular eye examinations are also recommended - especially in younger patients - as some develop lens abnormalities (cataracts) during treatment. Contact your CF specialist if you notice any new or worsening symptoms.

Q7. What is the step-by-step process for ordering through MedsPartner?

A - Visit the Triko product page and submit an order request - no payment required at this stage. Upload your valid prescription, and MedsPartner checks your country's import requirements and confirms the documentation needed. Once approved and payment is made, we facilitate compliant personal importation of the generic - which is delivered to your doorstep through international couriers. 

Q8. What if my insurance denies coverage or demands a high co-pay for Trikafta®?

A - Ask your doctor to submit a prior authorisation appeal supported by your mutation test results, lung function data, and clinical justification for ETI therapy. Vertex's GPS co-pay savings programme may reduce monthly copays for eligible commercially insured US patients. The HealthWell Foundation also provides copay assistance. If coverage still cannot be arranged at an affordable level, generic Triko from MedsPartner is an alternative that can be accessed via personal importation.

Q9. Are there other support options for accessing Trikafta® at a lower cost?

A - Vertex's GPS patient assistance programme provides free Trikafta® for uninsured US patients who meet income requirements. The Cystic Fibrosis Foundation maintains a financial assistance directory covering grants and state-level resources. For patients outside the US, or those who don't qualify for these programmes, MedsPartner's personal import pathway in association with CFBC is the most practical access route currently available.

Access to Trikafta® is finally becoming possible for more CF patients

Trikafta® changed what CF means for patients who could access it. For the majority who couldn't - due to Vertex's $370,000 annual list price - the arrival of Triko is genuinely significant. MedsPartner is helping translate the arrival of this affordable medicine into real access for patients worldwide.

Interested in accessing the generic version of Trikafta®? Write to us or place an order on our product page to be added to the waiting list. Our team is always here to answer your queries or facilitate personal import of the medicine to your doorstep.

About the Author - Aayyush Goyal has a background in healthcare consulting & pharmaceutical supply chains - with over a decade of experience in drug pricing, regulatory policy & patient rights. He has advised patients, advocacy groups & healthcare providers across 40+ countries on safe and compliant access to essential medicines. Through MedsPartner, Aayyush has overseen more than 30,000 successful patient deliveries worldwide, ensuring affordability without compromising safety or legality. He is a recognised advocate for ethical sourcing, generic access & cross-border care solutions, and has contributed insights on global drug access in healthcare forums, media publications & patient support networks.